Fig. 4: Disabling FAS signaling enhances CAR-T antitumor efficacy in vivo.
From: CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit
a, Experimental design to compare the in vivo antitumor efficacy of human T cells that express a 1928ζ CAR ± a FAS-dominant negative receptor (ΔFAS) against established Nalm6-luciferase (Luc) B-ALL. b–d, BLI (b), overall survival curves (c) and quantification of tumor burden (d) for Nalm6-Luc B-ALL-bearing NSG mice treated by i.v. injection with 5 × 105 tEGFR+ T cells transduced with an indicated vector. Pooled survival data from identically performed experiments using T cells from two unique donors is shown in c and is plotted as a Kaplan–Meier survival curve (tEGFR alone, n = 10; tEGFR-1928ζ, n = 15; tEGFR-1928ζ-ΔFAS, n = 15). Statistical comparisons were made using a log-rank test. Quantification of tumor burden as a function of time in mice treated with transduced T cells from an indicated donor measured using BLI (total flux) (d).
